Actionable news
All posts from Actionable news
Actionable news in ADRO: Aduro Biotech Inc,

Aduro Biotech Fails Phase 2 Pancreatic Cancer; Shares Fall 16%

Shares of Aduro Biotech (ADRO) tanked by 16.65% today after the company announced that it had failed its phase 2b "Eclipse" trial in patients with pancreatic cancer. The phase 2b trial was testing the company's vaccine immunotherapy CRS-207, which is the company's most advanced drug in the pipeline. For the phase 2b trial the company was testing their drug either alone or in combination with another drug, GVAX Pancreas, against chemotherapy.

The final results was that CRS-207 and GVAX Pancreas obtained a medial overall survival of 3.8 months, while CRS-207 alone performed better with an overall survival of 5.4 months, and chemotherapy alone obtained a median overall survival of...